Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Astex Forms Alliance With J&J's Janssen
June 16, 2008
| A version of this story appeared in
Volume 86, Issue 24
Astex Therapeutics will work with Janssen Pharmaceutica, a Johnson & Johnson company in Belgium, to develop anticancer drugs. In exchange for $37 million in upfront fees, research funding, and an equity investment in Astex, Janssen gets an exclusive license to compounds from the British firm's fibroblast growth factor receptor (FGFR) inhibitor program. Astex has discovered selective FGFR inhibitors using its fragment-based drug discovery platform. Astex could receive $500 million or more, excluding royalties, in milestone payments.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X